UK stocks notch two-month highs as U.S. inflation cools



(For a Reuters live blog on U.S., UK and European stock markets, click

or type LIVE/ in a news window.)

*

AstraZeneca jumps on raising earnings forecast

*

Centrica to buy back up to 5% of shares

*

U.S. October inflation up less than expected

*

FTSE 100 up 1.1%, FTSE 250 gains 3.9%

By Johann M Cherian and Sruthi Shankar

Nov 10 (Reuters) -

The UK's main stock indexes closed at near two-month highs on Thursday, joining a global rally sparked by cooling U.S. inflation that drove expectations of smaller interest rate hikes by the Federal Reserve.

The FTSE 100 .FTSE rose 1.1% to its strongest close since Sept. 13. However, a rally in the pound GBP=D3 checked further gains in the exporter-heavy index.

The domestically focussed FTSE 250 index .FTMC jumped 3.9% to post its biggest percentage gain in eight months.

The rally came as Wall Street's main indexes soared after data showed U.S.consumer prices rose less than expected in October, spurring bets that the Fed will hike interest rates by a smaller 50 basis points in December.

"U.S. inflation data has provided a welcome shot in the arm for markets, with the declines seen across both headline and core inflation bringing the kind of optimism that has been lacking without seeing non-energy related inflation turn lower," said Joshua Mahony, senior market analyst at online trading platform IG.

UK equities have climbed along with global stocks in recent weeks as hopes that the U.S. central bank will slow its pace of rate hikes and better-than-expected earnings offset data signalling a weakening domestic economy.

The midcap index has rallied nearly 17% off its October lows, but is still down as much on a year-to-date basis. The blue-chip FTSE 100 has bounced 8% from its trough, erasing nearly all of its annual declines.

A survey on Thursday showed British house prices fell for the first time in 28 months in October and rising mortgage costs threatened to put further pressure on the property market.

Among single stocks, AstraZeneca AZN.L rose 2.9% after the drugmaker raised its full-year adjusted earnings forecast on a boost from sales of its roster of cancer drugs.

Power company Centrica CNA.L climbed 7.4% after it forecast its annual adjusted earnings per share outlook to be at the top end of analysts' expectations, and announced a share buyback of up to 5% of its share capital.

WH Smith SMWH.L added 5.1% after the company, which sells everything from books and sandwiches to Bluetooth headphones, reinstated dividends and posted an annual profit.
Reporting by Johann M Cherian in Bengaluru; Editing by Sherry Jacob-Phillips, Uttaresh.V and Jonathan Oatis

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Gumagamit kami ng cookies para mabigyan ka ng mahusay na karanasan sa aming website. Magbasa pa o palitan ang iyong cookie settings.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.